C1q deposition in the renal allograft: a report of 24 cases

Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
Samar M SaidSamih H Nasr

Abstract

C1q nephropathy is an uncommon glomerular disease characterized by dominant or codominant mesangial staining for C1q in the absence of systemic lupus erythematosus. There are no series in the literature addressing the significance of C1q deposition in the renal allograft. We retrospectively analyzed 24 patients, most of whom were white (83%) and male (63%), with a mean age at transplant of 31 years. None of the patients were diagnosed with C1q nephropathy in the native kidney or had any features of systemic lupus erythematosus. The mean time from transplant to detection of mesangial C1q deposits was 37 months (>12 months in 71% of cases). Half of the patients had a preceding infection. The indication for biopsy was surveillance (63%) or graft dysfunction (37%). At biopsy, 52% had proteinuria (>1g/day in only 17%). The mean creatinine was 1.8 mg per 100 ml. Only 9% developed hematuria and none had hypoalbuminemia. The glomerular pattern on light microscopy was mesangial hypercellularity (46%), focal segmental glomerulosclerosis (21%), or no lesions (33%). All cases showed intense (>or=2+) dominant (67%) or codominant (33%) mesangial staining for C1q on immunofluorescence. Mesangial electron-dense deposits were seen in 82% of cas...Continue Reading

References

Oct 1, 1991·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·S S IskandarW B Lorentz
Aug 1, 1989·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·L TruongC L Pirani
Aug 1, 1985·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·J C Jennette, C G Hipp
Nov 13, 2001·Kidney International·C PonticelliA Tarantino
Sep 13, 2003·Kidney International·Glen S MarkowitzVivette D D'Agati
Oct 26, 2005·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Tanja Kersnik LevartAlenka Vizjak
Feb 24, 2006·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Yuko FukumaHiroshi Iwasaki
Oct 19, 2007·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·H AmerF G Cosio
Jul 25, 2008·Clinical Journal of the American Society of Nephrology : CJASN·Satoshi HisanoHiroshi Iwasaki
Jul 25, 2008·Journal of the American Society of Nephrology : JASN·Alenka VizjakJ Charles Jennette
Nov 21, 2008·Kidney International·Jon J SnyderBertram L Kasiske
Dec 17, 2008·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Craig S WongJohn R Brandt
Oct 13, 2009·Journal of the American Society of Nephrology : JASN·Hatem Amer, Fernando G Cosio

❮ Previous
Next ❯

Citations

Nov 28, 2013·Nephro-urology Monthly·Pavan Malleshappa, Mahesha Vankalakunti
Aug 8, 2015·Human Pathology·Giovanna A GiannicoAgnes B Fogo
Dec 8, 2015·Analytical Cellular Pathology (Amsterdam)·Joe DevasahayamUnni Pillai
Oct 27, 2016·Pediatric Transplantation·Isabel Roberti, Shefali Vyas
Sep 12, 2019·Pathology International·Anri SawadaYoji Nagashima

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Clinical Journal of the American Society of Nephrology : CJASN
Satoshi HisanoHiroshi Iwasaki
Pediatric Nephrology : Journal of the International Pediatric Nephrology Association
Tanja Kersnik LevartAlenka Vizjak
Journal of the American Society of Nephrology : JASN
Alenka VizjakJ Charles Jennette
© 2021 Meta ULC. All rights reserved